Deferasirox-induced urticarial vasculitis in a patient with myelodysplastic syndrome
An. bras. dermatol
;
92(5,supl.1): 59-61, 2017. tab, graf
Article
Dans Anglais
| LILACS
| ID: biblio-887080
ABSTRACT
Abstract Deferasirox is an iron chelator agent used in the treatment of diseases with iron overload, such as thalassemia and myelodysplastic syndrome. Although the majority of adverse reactions of deferasirox involve gastrointestinal symptoms and increase in serum creatinine and transaminases, skin rashes, such as maculopapular and urticarial eruptions, have also been reported. This study reports a case of myelodysplastic syndrome with urticarial vasculitis due to deferasirox therapy. Drug eruption was been confirmed by means of a challenge test, together with histopathological and clinical findings. To the best of our knowledge, we report the first case of deferasirox-induced urticarial vasculitis. Physicians should be aware of the possibility of urticarial vasculitis on deferasirox therapy and the fact that the discontinuation of the drug generally results in improvement.
Texte intégral:
Disponible
Indice:
LILAS (Amériques)
Sujet Principal:
Triazoles
/
Urticaire
/
Vascularite
/
Benzoates
/
Syndromes myélodysplasiques
/
Agents chélateurs du fer
/
Toxidermies
Limites du sujet:
Adulte très âgé
/
Femelle
/
Humains
langue:
Anglais
Texte intégral:
An. bras. dermatol
Thème du journal:
Dermatologie
Année:
2017
Type:
Article
Pays d'affiliation:
Turquie
Institution/Pays d'affiliation:
Istanbul Training and Research Hospital/TR
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS